Research Article

Peroxisome Proliferator-Activated Receptor-y Promotes Adipogenic Changes in Growth Plate Chondrocytes In Vitro

Lai Wang, Yvonne Y. Shao, and R. Tracy Ballock

Orthopaedic Research Center, Department of Orthopaedic Surgery and Biomedical Engineering, The Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Received 9 April 2006; Revised 8 July 2006; Accepted 10 July 2006

Chondrocytes and adipocytes are two differentiated cell types which are both derived from mesenchymal cells. The purpose of this study was to investigate whether peroxisome proliferator-activated receptor- γ (PPAR γ), a transcription factor involved in lineage determination during adipogenesis, is able to induce adipogenic differentiation in growth plate chondrocytes. Isolated epiphyseal chondrocytes were infected with a PPAR γ adenovirus or treated with the PPAR γ agonist ciglitazone. Both of these treatments resulted in lipid droplet accumulation and expression of the adipogenic markers aP2, lipoprotein lipase, and adipsin in chondrocytes. Proteoglycan matrix synthesis was decreased in the PPAR γ -infected cells, as was the expression of the chondrogenic genes Col2a1 and aggrecan. Growth plate cells transfected with a PPAR γ expression plasmid under the control of the collagen α 1(II) promoter also demonstrated a similar adipogenic changes. Terminal differentiation of growth plate chondrocytes induced by thyroid hormone was also inhibited by overexpression of PPAR γ and ciglitazone treatment, with decreased expression of alkaline phosphatase and Runx2/Cbfa1 genes. These in vitro data suggest that PPAR γ is able to promote adipogenic differentiation in growth plate chondrocytes, while negatively regulating chondrogenic differentiation and terminal differentiation.

Copyright © 2006 Lai Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Longitudinal growth of the skeleton is a result of endochondral ossification that occurs at the growth plate [1]. Endochondral ossification is a multistep process that includes differentiation of mesenchymal cells into chondrocytes, cell proliferation, hypertrophic differentiation, matrix mineralization, apoptosis, vascular invasion, and eventually the replacement of the cartilage by bone.

The first step of growth plate development is the commitment of mesenchymal stem cells to the chondrogenic lineage. Mesenchymal stem cells exhibit a high differentiation plasticity. They are capable of differentiating into chondrocytes, osteoblasts, adipocytes, and other tissues of mesenchymal origin [2]. Interconversion between mesenchymal phenotypes is thought to be under control of specific transcription factors, including the Sox family in chondrogenesis [3], Runx2/Cbfa1 in osteogenesis [4], and PPARy (peroxisome proliferator-activated receptor- γ), and C/EBP (CCAAT/enhancer-binding protein) in adipogenesis [5].

PPAR γ is a key transcriptional regulator of adipogenesis [5]. PPAR γ is also expressed in preosteoblastic cells and is thought to play a role in regulation of bone metabolism.

PPARy and PPARy activators inhibit the maturation of preosteoblastic cells to osteoblasts [6–8]. Free fatty acids activate PPARs and induce adipocyte-like differentiation of osteosarcoma cell lines [6]. Lecka-Czernik et al observed that PPARy2 negatively regulates stromal cell plasticity by suppressing expression Osf2/Cbfa1 and osteoblast-like biosynthetic activity, while promoting differentiation to adipocytes [7]. Conversely, PPARy insufficiency enhances osteogenesis through increased osteoblast formation from bone marrow progenitors. Homozygous PPARy-deficient ES cells fail to differentiate into adipocytes, but increase bone mass by stimulating osteoblastogenesis from bone marrow progenitors [8].

Transdifferentiation of chondrocytes to adipocytes has been previously reported by Heermeier et al, who observed that chondrocytes of the mouse xiphoid process undergo transdifferentiation into adipocytes in the presence of 10% fetal calf serum [9].

Based on the finding that PPARy is expressed in growth plate chondrocytes [10], as well as the evidence that PPARy is able to compete with the thyroid hormone receptor (TR) for binding to retinoic acid receptor X to inhibit growth plate cell hypertrophy [11], the purpose of this study was to investigate whether PPARy and its ligands are able to promote adipogenic differentiation and suppress chondrogenic differentiation in growth plate chondrocytes.

MATERIALS AND METHODS

Cell culture

Chondrocytes were isolated from the resting zone of the distal femoral growth plate of 2-day old neonatal Sprague-Dawley rats by sequential digestion in trypsin/EDTA (Invitrogen, Carlsbad, Calif) for 1 hour at 37°C, followed by 0.3% collagenase type I (Worthington, Lakewood, NJ) for 4 hours at 37°C [12]. Cells were resuspended in DMEM/F12 medium (Invitrogen) supplemented with a defined media supplement (ITS+1, Sigma, St Louis, Mo) and plated in monolayer at a density of 5×10^5 cells/cm², or in a pellet culture of 1×10^5 cells/mL as indicated [12]. Tri-iodothyronine (T3, Sigma) at a concentration of 100 ng/mL and ciglitazone (BioMol, Plymouth Meeting, Pa) at a concentration of 5μ M were added to the medium as indicated.

Immunoblotting

Total cellular protein was extracted from chondrocytes treated with 5μ M of ciglitazone using RIPA buffer [9]. An equal amount of protein was subjected to SDS-PAGE, and transferred onto nitrocellulose membranes. The blots were incubated with anti-PPAR γ and anti-actin (Santa Cruz Biotechnology, Santa Cruz, Calif) followed by a HRP-conjugated secondary antibody. Immunoreactive proteins were visualized by Western Blotting Chemiluminescence Luminol Reagent (Santa Cruz Biotechnology). Immunoblot bands were quantitated with Kodak 1D Image Analysis Software (Eastman Kodak Company, Rochester, NY).

Adenovirus infection

Recombinant adenovirus carrying PPARy1 (Ad-PPARy) was kindly provided by Dr J. L. Jameson (Northwestern University Medical School, Chicago, Ill). Ad-PPARy contains mouse PPARy1 cDNA driven by the CMV promoter/enhancer with an SV40 polyadenylation sequence [13]. Ad-Gal, which contains β -galactosidase driven by CMV promoter, was used to evaluate the efficiency of gene transduction. Eighteen hours after plating in monolayer, growth plate chondrocytes were infected with adenoviral vectors at a multiplicity of infection (MOI) of 100. Fresh media were added 24 hours after infection and incubated for 72 hours to collect the cell protein extracts. β -galactosidase expression was detected in 80% of cells after 24 hours of infection with Ad-Gal. Expression of introduced PPARy genes was confirmed by immunoblot.

Plasmid construction and transient transfection

The full-length cDNA of mouse PPARy was excised by *Asp718/NheI* digestion from pCMX-PPARy (kindly provided

by Dr R. Evans, Salk Institute, La Jolla, Calif). The ends of this fragment were blunted with Klenow polymerase and ligated to a blunt-ended BamHI site in the p1757 plasmid containing the rat α 1(II) collagen promoter (kindly provided by Dr Y. Yamada, NIDR, Bethesda, Md) [14]. The cDNA encoding the mouse PPAR*y* was thus located downstream of the rat α 1 (II) collagen promoter element (-977 to +110). Nucleotide sequence analysis confirmed the correct orientation of the PPAR*y* cDNA.

Growth plate cells were transfected with $10 \mu g$ of p1757-PPARy or p1757 as a negative control by lipofection (Fugene 6, Roche, Indianapolis, Ind) in the presence of 4 units/mL of hyaluronidase. Sixteen hours later, the cells were trypsinized and centrifuged to pellets cultured in DMEM/F12 plus ITS+ supplements [11].

Histochemical staining

For the analysis of adipogenic differentiation, adipogenesis and lipid accumulation in the growth plate cells were examined by staining with Oil Red-O. After 10 days of culture, cells were washed gently with PBS followed by staining with a filtered solution of 0.5% Oil Red-O (Sigma) in 60% isopropanol for 20 minutes. After washing cells with PBS three times, cells were kept in 75% glycerol solution and observed under a phase-contrast microscope.

Alcian blue staining was used to detect chondrocytespecific proteoglycans at 10 days of culture. Cells were stained with a 4 : 1 ratio of 0.1 M HCl/0.5% Alcian blue stock (0.5% Alcian blue in 95% ethanol) overnight at 37°C in a humidified atmosphere. Cells were then washed twice with PBS to stop reaction and once with 70% ethanol to reduce background.

For alkaline phosphatase (ALP) staining, cultured plates were rinsed with PBS at 10 days of culture, fixed in 3.7% formaldehyde at room temperature for 10 minutes, and stained in the dark for 30 minutes in a 0.1 M Tris-HCl solution (pH 8.5) containing 0.2 mg/mL of Napthol AS-MX phosphate and 0.6 mg/mL of Fast Blue BB salt (Sigma).

Quantitative real-time RT-PCR

The expression of chondrocyte or adipocyte-specific RNA markers was analyzed using quantitative real-time RT-PCR. Total RNA was isolated from cultured growth plate chondrocytes using the RNeasy Kit (Qiagen, Valencia, Calif) 4 days after adenovirus infection or plasmid transfection. Reverse transcription was performed using random primers and Superscript III (Invitrogen). Real-time PCR reactions were conducted in an ABI Prism 7700 Sequence Detection System using SYBR Green PCR core reagents (Applied Biosystems, Foster City, Calif). The comparative C_T method ($\Delta\Delta C_T$ method) was utilized for relative quantitation of gene levels of expression. 18S rRNA was used as an internal control for normalization of target gene expression. The forward and reverse primers for the amplifications are listed in Table 1.



FIGURE 1: Ciglitazone promotes PPARy expression in the growth plate chondrocytes. Growth plate chondrocytes in pellet cultures were incubated in the presence or absence of 5μ M of ciglitazone for 4 days. (a) Total RNA was collected and real-time PCR was performed to quantitate PPARy mRNA levels, which were normalized with respect to endogenous 18S rRNA levels. (b) Proteins were extracted for immunoblotting to detect PPARy expression and the immunoblots quantitated using Kodak 1D image analysis software. Actin was used as an internal control.

Statistical analysis

The data for real-time PCR are represented as mean \pm standard deviation. Values are assessed by one-way ANOVA with the Bonferroni post-hoc test and Student *t* test at a significance level of *P* < .05.

RESULTS

Ciglitazone upregulates PPARy expression in growth plate chondrocytes

Treatment of growth plate cells with ciglitazone resulted in increases of both PPAR γ mRNA and protein. PPAR γ mRNA was increased 9-fold after addition of ciglitazone (5 μ M) for 4 days (Figure 1(a)), while PPAR γ protein levels were increased approximately 5-fold (Figure 1(b)).

PPARy induces adipogenic differentiation in growth plate chondrocytes

Phase-contrast microscopy demonstrated that the Ad-PPARy-infected growth plate chondrocytes acquired the morphology characteristic of adipocytes after culture in monolayer for 10 days. Approximately 50% of the cells had accumulated vacuoles, which were positive for Oil Red-O staining of lipid accumulation (Figure 2(a)). The control cells infected with Ad-Gal demonstrated few Oil Red-O positive vacuoles. Cells treated with 5 μ M of ciglitazone alone for

TABLE 1: Primer sequences used for real-time PCR.

Genes	Primers	
aP2	Forward	5'-GGCTTCGCCACCAGGAA-3'
	Reserve	5'-CCCTTCTACGCTGATGATCAAGT-3'
LPL	Forward	5'-GGGTCGCCTGGTCGAAGT-3'
	Reserve	5'-AAAGTGCCTCCATTGGGATAAA-3''
Adipsin	Forward	5'-CCGATGTCCTGCAGCAACT-3'
	Reserve	5'-CATGGTACGTGCGCAGATTG-3'
COL2A1	Forward	5'-GGTGGAGCAGCAAGAGCAA-3'
	Reserve	5'-CGTCGCCGTAGCTGAAGTG-3'
Aggrecan	Forward	5'-CTAGCTGCTTAGCAGGGATAACG-3'
	Reserve	5'-CCGCAGAGTCACAAAGACCAA-3'
ALP	Forward	5'-GCCGGCAGGACACAGACT-3'
	Reserve	5'-GGTTGCAGGGTCTGGAGAGTATA-3'
Runx2/	Forward	5'-TTTAGGGCGCATTCCTCATC-3'
Cbfa1	Reserve	5'-GGAGGGCCGTGGGTTCT-3'
18S	Forward	5'-AGTCCCTGCCCTTTGTACACA-3'
	Reserve	5'-GATCCGAGGGCCTCACTAAAC-3'

10 days also showed enhanced Oil Red-O staining (20% of the total cells), while the combination of ciglitazone treatment and Ad-PPARy infection further enhanced lipid accumulation (over 70% of cells staining positively with Oil Red-O).



FIGURE 2: Adipogenic changes in the growth plate cells in which PPARy was overexpressed or cells treated with ciglitazone. (a) Growth plate cells were infected with Ad-PPARy or Ad-Gal followed by a 10-day incubation in the presence or absence of ciglitazone (5μ M). Cells were observed under the phase contrast microscope with 10-fold magnification. Oil Red-O staining shows lipid accumulation within the cells. (b) Quantitative real-time PCR analysis of the adipogenic marker genes aP2, LPL, and adipsin, in growth plate cells at day 4 of the culture. Ad-Gal- infected cells were used as controls. Gene expression levels were normalized with respect to endogenous 18S rRNA. **P* < .05 versus the expression in control cells.

To characterize the phenotype of the transformed cells in more detail, the cells were cultured in three-dimensional cell pellets and the expression of adipocyte differentiation marker genes examined by real-time RT-PCR at day 4 of the culture period. Compared with the control samples, the levels of expression of the adipogenic marker genes aP2, LPL,and adipsin increased 6.6-, 4.4- and 4.6-folds, respectively, on day 4 in the 5μ M ciglitazone-treated cells (Figure 2(b)). Expression of aP2, LPL, and adipsin genes increased in the Ad-PPAR*y*-infected cells by 75.1-, 40.2-, and 76.6-folds, respectively in the absence of ciglitazone, and 101.1-, 44.9-, and 96.3-folds, respectively, in the presence of ciglitazone (5μ M).

In order to address the possibility that PPARy was acting on an undifferentiated mesenchymal stem cell as opposed to a differentiated chondrocyte, p1757-PPARy expression plasmid was generated in which a PPARy cDNA was placed under the transcriptional control of the rat COL2A1 gene promoter and enhancer sequences. Oil Red-O staining of the p1757-PPARy-transfected cells maintained in threedimensional pellet culture for 10 days showed markedly increased lipid accumulation (Figure 3(a)). Real-time RT-PCR demonstrated that aP2, LPL, and adipsin mRNA expressions were upregulated 21.1-, 12.9-, and 17.9-folds, respectively, compared with the cells transfected with the empty p1757 plasmid at day 4 after transfection (Figure 3(b)).

PPAR γ induces loss of chondrocytic phenotype in growth plate cells

Alcian blue staining was used to detect the accumulation of cartilage-specific proteoglycan. At day 10, the control cultures of growth plate cells still accumulated abundant proteoglycan (Figure 4(a)). No significant difference in proteoglycan accumulation was observed in the growth plate chondrocytes that were treated with 5μ M of ciglitazone alone. Compared to the Ad-Gal-infected cells, the Ad-PPAR*y*-infected cultures were stained less intensely with Alcian blue, especially the surrounding of the cells that contained vacuoles. Addition of 5μ M of ciglitazone to the Ad-PPAR*y*-infected cultures resulted in a further decrease in proteoglycan vacuum and the surrounding of the cells that contained vacuoles. Addition of 5μ M of ciglitazone to the Ad-PPAR*y*-infected cultures resulted in a further decrease in proteoglycan matrix.



FIGURE 3: Adipogenic changes in the growth plate chondrocytes transfected with a PPARy plasmid under the control of a collagen α 1(II) promoter. (a) Growth plate cells were transfected with the p1757-PPARy plasmid. Transfected cells were maintained in pellet cultures for 10 days, followed by Oil Red-O staining. (b) Quantitative PCR analysis of adipogenic markers of the p1757-PPARy transfected growth plate cells at day 4 after transfection. Cells transfected with the empty p1757 plasmid were used as controls. Gene expression levels were normalized with respect to endogenous 18S rRNA. **P* < .05 versus the expression in control cells.

Quantitative RT-PCR demonstrated that the chondrocyte-specific genes COL2A1 and aggrecan were downregulated by both PPARy and ciglitazone (Figure 4(b)). Treatment with $5 \,\mu$ M of ciglitazone for 4 days resulted in a 33% decrease of COL2A1 mRNA and a 17% decrease in aggrecan mRNA expression. Combination of both PPARy adenovirus and $5 \,\mu$ M of ciglitazone resulted in a 50% decrease of COL2A1 mRNA and a 22% decrease in aggrecan mRNA expression.

PPAR γ inhibits T3-induced hypertrophy and mineralization in growth plate chondrocytes

Thyroid hormone is a crucial regulator in growth plate chondrocyte hypertrophic differentiation and matrix mineralization [15–17]. Growth plate cells treated with thyroid hormone and 5μ M of ciglitazone demonstrated decreased alkaline phosphatase histochemical staining compared to cells treated with T3 alone (Figure 5(a)). Quantitative RT-PCR analysis of growth plate cells in pellet cultures treated with T3 and 5μ M of ciglitazone for 4 days confirmed a 64% decrease in ALP mRNA compared to cells treated with T3 alone (Figure 5(b)). Infection with PPAR γ adenovirus in cells treated with T3 also decreased expression of ALP mRNA approximately 71% in the absence of ciglitazone, and 76% in the presence of 5 μ M of ciglitazone. Runx2/Cbfa1 is expressed in chondrocytes as they initiate chondrocyte hypertrophy and maturation. Ciglitazone at a concentration of 5 μ M decreased the T3-induced expression of Runx2 by 36%. Ad-PPARy infection decreased the expression of Runx2 mRNA by 54% in the absence of ciglitazone and by 66% in the presence of 5 μ M of ciglitazone.

DISCUSSION

Growth plate chondrocytes originate from multipotential mesenchymal stem cells that can differentiate into other cell types including adipocytes. We present evidence in this study that growth plate cells continue to display differentiation plasticity and are able to undergo adipogenic changes and a reciprocal decrease of chondrocytic markers when PPARy is overexpressed.

It has been previously reported that chondrocytes are able to transdifferentiate into adipocytes in vitro [9]. The fatty acid content of the serum added to the culture media has been implicated as a potential cause of this transdifferentiation process [6]. We used a serum-free culture system in these experiments to avoid the possibility that fatty acids in the serum might induce the adipogenic changes observed.



FIGURE 4: Loss of the chondrogenic phenotype in growth plate cells in which PPARy was overexpressed or cells treated with ciglitazone. (a) Growth plate cells were infected with Ad-PPARy or Ad-Gal followed by a 10-day incubation in the presence or absence of ciglitazone (5 μ M). Alcian blue staining shows the accumulation of chondrocyte-specific matrix. (b) Quantitative PCR analysis of chondrogenic genes, COL2A1, and aggrecan, in growth plate cells infected with Ad-PPARy or treated with ciglitazone at day 4 of treatment. Ad-Gal-infected cells were used as controls. Gene expression levels were normalized with respect to endogenous 18S rRNA. * P < .05 versus the expression in control cells.

Ciglitazone is one of the thiazolidinedione classes of antidiabetic compounds which can activate PPARy [18]. Ciglitazone not only increases endogenous PPARy transcriptional activity [11], but also upregulates PPARy mRNA and protein expression in growth plate chondrocytes, as observed in this study.

Activation of endogenous PPARy by ciglitazone or adenoviral overexpression of PPARy in growth plate chondrocytes resulted in acquisition of adipogenic features in both highdensity monolayer cultures and three-dimensional pellet cultures of growth plate chondrocytes, as evidenced by cell morphology, lipid accumulation, and expression of adipocyte marker genes aP2, LPL, and adipsin. Growth plate cells maintained in monolayer cultures seemed to acquire features of the adipocytic phenotype and lose features of the chondrocytic phenotype more readily than those in the pellet cultures (data not shown).

To confirm that the adipocyte-like cells were differentiated directly from chondrocytes and not from other cell types such as undifferentiated mesenchymal stem cells, growth plate cells were transfected with a PPAR γ plasmid under the control of a collagen α 1(II) promoter. Acquisition of the adipogenic phenotype in these transfected cells was similar to the cells infected with an adenovirus encoding PPAR γ and driven by the CMV promoter/enhancer. While PPAR γ and ciglitazone converted cells of the chondrocyte lineage to an adipocytic phenotype, features of the chondrocyte phenotype were simultaneously suppressed. PPAR γ inhibited the ability of chondrocytes to terminally differentiate into hypertrophic cells, and suppressed the expression of genes encoding chondrocyte-specific extracellular matrix proteins.

Slipped capital femoral epiphysis (SCFE) is an obesityrelated hip disease in children characterized by weakness in the growth plate of the proximal femur, delayed skeletal maturation, and eventual mechanical failure of the physis [19-21]. We speculate that obesity may induce the expression of PPARy isoforms in growth plate chondrocytes, resulting in phenotypic changes that interrupt normal skeletal maturation at the growth plate through interference with thyroid hormone signaling. This interference with thyroid hormone-mediated terminal differentiation of growth plate cells and resulting decreased mineralization of the cartilage matrix would be expected to reduce the resistance of the growth plate to shear stresses. Therefore this delay in maturation at the growth plate, combined with both the increased mechanical stress resulting from increased body weight and the decreased shear stress resulting from delayed maturation, may combine to cause the proximal femoral epiphysis to slip.



FIGURE 5: Inhibition of T3-induced hypertrophy and mineralization in the growth plate cells by PPAR γ overexpression or ciglitazone treatment. (a) Growth plate cells were treated with T3 (100 ng/mL) in the presence or absence of ciglitazone (5 μ M) for 10 days. Alkaline phosphatase (ALP) staining was used as a marker of terminal differentiation of growth plate chondrocytes. Positive stainings were colored in dark blue. Negative-stained background was colored in light green. (b) Quantitative PCR analysis of ALP and Runx2 genes 4 days after growth plate cells were infected with Ad-PPAR γ or treated with ciglitazone. Ad-Gal-infected cells without T3 or ciglitazone treatment were used as controls. Gene expression levels were normalized with respect to endogenous 18S rRNA. *P < .05 versus the expression in the Ad-Gal-infected cells with T3treatment.

ACKNOWLEDGMENTS

We thank Dr J. L. Jameson (Northwestern University Medical School, Chicago, Ill) for providing the recombinant adenovirus carrying PPARy1, Dr. R. Evans (Salk Institute, La Jolla, Calif) for providing the PPARy expression plasmids, and Dr Y. Yamada (National Institutes of Health, Bethesda, Md) for providing p1757 plasmid. This work was supported by a grant from the National Institutes of Health to R. Tracy Ballock (1 RO1 AR47955).

REFERENCES

- Ballock RT, O'Keefe RJ. Physiology and pathophysiology of the growth plate. *Birth Defects Research Part C: Embryo Today: Re*views. 2003;69(2):123–143.
- [2] Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. *Arthritis Research and Therapy*. 2003;5(1):32–45.

- [3] de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. *Matrix Biology*. 2000;19(5):389–394.
- [4] Komori T. Runx2, a multifunctional transcription factor in skeletal development. *Journal of Cellular Biochemistry*. 2002;87(1):1–8.
- [5] Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. *Genes & Development*. 2000;14(11):1293–1307.
- [6] Diascro DD Jr, Vogel RL, Johnson TE, et al. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. *Journal of Bone and Mineral Research*. 1998;13(1):96–106.
- [7] Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARy2. *Journal of Cellular Biochemistry*. 1999;74(3):357– 371.
- [8] Akune T, Ohba S, Kamekura S, et al. PPARy insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. *The Journal of Clinical Investigation*. 2004;113(6):846–855.
- Heermeier K, Strauss PG, Erfle V, Schmidt J. Adipose differentiation of cartilage in vitro. *Differentiation*. 1994;56(1-2):45– 53.
- [10] Shao YY, Wang L, Hicks DG, Tarr S, Ballock RT. Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. *Journal of Orthopaedic Research*. 2005;23(5):1139–1145.
- [11] Wang L, Shao YY, Ballock RT. Peroxisome proliferator activated receptor-y (PPARy) represses thyroid hormone signaling in growth plate chondrocytes. *Bone*. 2005;37(3):305–312.
- [12] Ballock RT, Reddi AH. Thyroxine is the serum factor that regulates morphogenesis of columnar cartilage from isolated chondrocytes in chemically defined medium. *Journal of Cell Biology*. 1994;126(5):1311–1318.
- [13] Park Y, Freedman BD, Lee EJ, Park S, Jameson JL. A dominant negative PPARy mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. *Diabetologia*. 2003;46(3):365–377.
- [14] Horton W, Miyashita T, Kohno K, Hassell JR, Yamada Y. Identification of a phenotype-specific enhancer in the first intron of the rat collagen II gene. *Proceedings of the National Academy of Sciences of the United States of America*. 1987;84(24):8864– 8868.
- [15] Bohme K, Conscience-Egli M, Tschan T, Winterhalter KH, Bruckner P. Induction of proliferation or hypertrophy of chondrocytes in serum-free culture: the role of insulin-like growth factor-I, insulin, or thyroxine. *Journal of Cell Biology*. 1992;116(4):1035–1042.
- [16] Burch WM, Lebovitz HE. Triiodothyronine stimulates maturation of porcine growth-plate cartilage in vitro. *Journal of Clinical Investigation*. 1982;70(3):496–504.
- [17] Carrascosa A, Ferrandez MA, Audi L, Ballabriga A. Effects of triiodothyronine (T3) and identification of specific nuclear T3-binding sites in cultured human fetal epiphyseal chondrocytes. *Journal of Clinical Endocrinology and Metabolism*. 1992;75(1):140–144.
- [18] Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor *y* (PPAR*y*). *Journal of Biological Chemistry*. 1995;270(22):12953–12956.

- [19] Kelsey JL, Acheson RM, Keggi KJ. The body build of patients with slipped capital femoral epiphysis. *American Journal of Diseases of Children*. 1972;124(2):276–281.
- [20] Sorensen KH. Slipped upper femoral epiphysis. Clinical study on aetiology. Acta Orthopaedica Scandinavica. 1968;39(4): 499–517.
- [21] Loder RT. Slipped capital femoral epiphysis. *American Family Physician*. 1998;57(9):2135–2142, 2148–2150.